Blog > US Stocks and Markets > Can Pfizer (PFE:NYSE) Recover?
 | Email This Article Email This Article  | 

Can Pfizer (PFE:NYSE) Recover?

Posted June 27, 2008

“When you look at the PFE chart, you should stretch it out as far as possible. That’s because this company is trading lower than any point in the last ten years. But why?” — Charles Delvalle

by Charles Delvalle

Baltimore – (TFN): I typically don’t cover pharmaceutical stocks because, in all honesty, the sector bores me a little. Something about hormones and cells just puts me to sleep. But I couldn’t pass up the one Frank Y. wanted me to cover…

I liked your comments on GE.

Is Pfizer in the same position, is it a falling knife, or has it bottomed?

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Receive your FREE subscription to Investor’s Daily Edge today!

Investor’s Daily Edge is a free investment newsletter that’s delivered by email before the market opens. In each weekday issue you’ll receive clear recommendations and practical strategies for protecting your portfolio and multiplying your money – whether the market is rising or falling.

Investor’s Daily Edge is written by a select group of market experts, each with their own style of investing. So whether you are a long-term investor, a short term trader, or a prudent speculator, you can count on useful advice you can take to the bank. Sign up today and get our free ‘must read’ special report: Learning from a legend: How Warren Made His Billions.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Pfizer (PFE:NYSE) – the maker of the ever-popular little blue pill.

Describing them as a falling knife, though, is extremely appropriate. When you look at the PFE chart, you should stretch it out as far as possible. That’s because this company is trading lower than any point in the last ten years.
But why?

Earnings dropped 17% last quarter and revenue dropped 5%. Why? Pfizer lost market exclusivity for Zoloft and Norvasc. This loss comes after they reduced their workforce by 10,000 people.

But the company is trying to right the ship. Read on to learn whether Pfizer’s attempts will be successful.

****Make sure you sign up for our free TFN News Feed for breaking news, special reports and new financial videos. You can pick your favorite reader . Or if you prefer, you can have or free daily email delivered to your inbox .

Related Articles


Posted by TFN-US · Filed Under US Stocks and Markets 

Comments

close Reblog this comment
Powered by Disqus · Learn more
blog comments powered by Disqus